Pharmacotherapy in cardiovascular diseases and vascular interventions

• References

• 1 Hennekens CH, Schror K, Weisman S. et al. Terms and conditions: semantic complexity and aspirin resistance. Circulation 2004; 110: 1706-8.
• 2 Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175-81.
• 3 Dieppe PA, Ebrahim S, Martin RM. Lessons from the withdrawal of rofecoxib. Br Med J 2004; 329: 867-8.
• 4 Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-32.
• 5 Cattaneo M. Aspirin and clopidogrel. efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004 Sep 23 [Epub ahead of print].
• 6 Patrono C, Coller B, FitzGerald GA. Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
• 7 Grossmann R, Sokolova O, Schnurr A. et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-6.
• 8 Ahnadi C, Boughrassa F, Chapman-Montgomery S. et al. Comparison of two methods to assess variability of platelet response to antiplatelet therapies in patients with acute coronary syndrome undergoing angioplasty. Thromb Haemost 2004; 92: 1207-13.
• 9 Schroer K, Weber AA, Hohlfeld T. Clopidogrel “resistance”. Thromb Haemost 2004; 92: 229-31.
• 10 Taubert D, Kastrati A, Harlfinger S. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-6.
• 11 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
• 12 Xiao T, Takagi J, Coller BS. et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004 Sep 19 [Epub ahead of print].
• 13 Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 02: 15-28.
• 14 Lehrke S, Giannitsis E, Katus HA. Admission troponin T, older age and male gender identify patients with improved myocardial tissue perfusion after Abciximab administration for ST-segment myocardial infarction. Thromb Haemost 2004; 92: 1214-20.
• 15 Cox D. Oral GPIIb/IIIa antagonists: what went wrong?. Curr Pharm Des 2004; 10: 1587-96.
• 16 Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003; 02: 703-16.
• 17 Schwarz M, Roettgen P, Takada Y. et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin αIιββ3 designed by subtractive selection from naive human phage libraries. FASEB J. 2004 18. November 1 [Epub ahead of print].
• 18 Bussey H, Francis JL. Heparin Consensus Group. Heparin overview and issues. Pharmacotherapy 2004; 24: 103S-107S.
• 19 Becker R, Alexander J, Dyke C. et al. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost 2004; 92: 1182-93.
• 20 Wiggins BS, Spinler S, Wittkowsky AK. et al. Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty. Pharmacotherapy 2002; 22: 1007-18.
• 21 Gustafsson D, Bylund R, Antonsson T. et al. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004; 03: 649-59.
• 22 Peng CY, Pan SL, Guh JH. et al. The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb Haemost 2004; 92: 1232-9.
• 23 Becker R, Alexander J, Li YF. et al. Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a. A direct and selective antagonist. Thromb Haemost 2004; 92: 1229-31.
• 24 Iwatsuki Y, Kawasaki T, Hayashi K. et al. combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice. Thromb Haemost 2004; 92: 1221-8.
• 25 Welsh R, Armstrong P. A marriage of enhancement: fibrinolysis and conjunctive therapy. Thromb Haemost 2004; 92: 1194-200.
• 26 Alehagen U, Dahlström U, Lindahl T. Elevated D-dimer level is an independent risk factor for cardiovascular death in out-patients with symptoms compatible with heart failure. Thromb Haemost 2004; 92: 1250-8.
• 27 Mannila MN, Silveira A, Hawe E. et al. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe: effects of β-fibrinogen genotype and environmental factors. The HIFMECH Study. Thromb Haemost 2004; 92: 1240-9.
• 28 Blake GJ, Ridker PM. Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002; 252: 283-94.
• 29 Anand SX, Viles-Gonzalez JF, Badimon JJ. et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-84.